Maccura Biotechnology Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 0.59%

Maccura Biotechnology Co Ltd (300463) has an Asset Resilience Ratio of 0.59% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Maccura Biotechnology Co Ltd (300463) total assets for the complete picture of this company's asset base.

Liquid Assets

CN¥47.02 Million
≈ $6.88 Million USD Cash + Short-term Investments

Total Assets

CN¥7.99 Billion
≈ $1.17 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2025)

This chart shows how Maccura Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. See Maccura Biotechnology Co Ltd (300463) net asset quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Maccura Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Maccura Biotechnology Co Ltd (300463) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥47.02 Million 0.59%
Total Liquid Assets CN¥47.02 Million 0.59%

Asset Resilience Insights

  • Limited Liquidity: Maccura Biotechnology Co Ltd maintains only 0.59% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Maccura Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio

Compare Maccura Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
Diagnostics & Research 0.14%
SMO ClinPlus Co. Ltd.
SHE:301257
Diagnostics & Research 15.78%
Healius Ltd
AU:HLS
Diagnostics & Research 0.06%
RHYTHM Biosciences Ltd
AU:RHY
Diagnostics & Research 2.74%
Check-Cap Ltd.
NASDAQ:MBAI
Diagnostics & Research 2.90%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%

Annual Asset Resilience Ratio for Maccura Biotechnology Co Ltd (2015–2025)

The table below shows the annual Asset Resilience Ratio data for Maccura Biotechnology Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.63% CN¥50.18 Million
≈ $7.34 Million
CN¥7.99 Billion
≈ $1.17 Billion
-0.13pp
2024-12-31 0.75% CN¥60.06 Million
≈ $8.79 Million
CN¥7.98 Billion
≈ $1.17 Billion
-3.08pp
2023-12-31 3.83% CN¥311.14 Million
≈ $45.53 Million
CN¥8.12 Billion
≈ $1.19 Billion
-4.30pp
2022-12-31 8.13% CN¥663.72 Million
≈ $97.12 Million
CN¥8.16 Billion
≈ $1.19 Billion
+5.23pp
2017-12-31 2.90% CN¥104.00 Million
≈ $15.22 Million
CN¥3.58 Billion
≈ $524.33 Million
-8.92pp
2016-12-31 11.82% CN¥319.00 Million
≈ $46.68 Million
CN¥2.70 Billion
≈ $394.85 Million
-15.16pp
2015-12-31 26.98% CN¥640.00 Million
≈ $93.65 Million
CN¥2.37 Billion
≈ $347.12 Million
--
pp = percentage points

About Maccura Biotechnology Co Ltd

SHE:300463 China Diagnostics & Research
Market Cap
$836.15 Million
CN¥5.71 Billion CNY
Market Cap Rank
#10001 Global
#2757 in China
Share Price
CN¥9.45
Change (1 day)
-1.66%
52-Week Range
CN¥9.45 - CN¥14.20
All Time High
CN¥59.01
About

Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of in vitro diagnostic products; and provides related services for medical laboratories in China and internationally. The company offers laboratory automation solutions, such as hematology analysis workstations; immunoassay products, such as chemiluminescence analyzers and reagents; molecular products, such a… Read more